Nadia B. B.
- Country
- France
- Department
- Neurologie Pédiatrique
Research Overview
- Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of Oral Fenfluramine Hydrochloride in Participants with Rett Syndrome
- Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecal ION582 in Angelman Syndrome Patients
- Long-Term Safety and Efficacy Evaluation of GTX-102 in Angelman Syndrome Patients
Data & Insights
Has run more than one trial at 6 of 38 partner sites.
Specializations
Neurodevelopmental Disorders
This investigator specializes in treating complex neurodevelopmental conditions, with particular expertise in Angelman syndrome and its therapeutic management.
- Novel therapeutic approaches for Angelman syndrome
- Intrathecal medication administration
- Long-term treatment evaluation
The research focus includes assessment of innovative therapeutic compounds and their safety profiles in treating genetic neurological conditions.
Genetic Disorders
The investigator conducts research into TBR1-related neurocognitive disorders, exploring targeted treatment approaches using established compounds.
- TBR1 gene variant disorders
- Adaptive behavior assessment
- Extended treatment protocols
Clinical investigations focus on evaluating therapeutic interventions for patients with confirmed genetic variants affecting cognitive function.
Treatment Development
Expertise in conducting longitudinal therapeutic trials examining both novel and established treatments for rare neurological conditions.
- Safety and efficacy evaluation
- Long-term patient monitoring
- Pharmacological interventions
The research encompasses comprehensive assessment of treatment outcomes in rare genetic disorders affecting neurological function.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.